

Anti-CD3 & GD2 Reference Antibody (Nivatrotamab)

Catalog # APR11614

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P07766 & NA
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-scFv

Additional Information


Target/Specificity	CD3,GD2
Expression system	CHO

Protein Information


Images




Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) is 100.00%, determined by SEC-HPLC.




Nivatrotamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Nivatrotamab bound to huCD3e-jurkat cells, and the EC50 was 3.481 nM.



Nivatrotamab bound to hu GD2-293 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Nivatrotamab bound to hu GD2-293 cells, and the EC50 was 68.100 nM.



Co-incubation of Nivatrotamab with Jurkat cells, then with the addition of hu GD2-his-293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Nivatrotamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.979 nM.



The detected molecular weight of Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) is 200.83 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.